University of California, San Francisco

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

Retrieved on: 
Thursday, June 8, 2023
University, PD, Comparison, Low back pain, NSF, E pluribus unum, DCLP, National Science Foundation, University of California, San Francisco, Department of Medicine – University of Pamplona, Biomarker, ACON, Doctor of Philosophy, Meta-analysis, CO, Monte Carlo, Pain, Patient, Physician, Algorithm, CDMI, Annual general meeting, ICER, ASPN, National Science Foundation: Under the Microscope, Policy, Lumbar disc disease, International Society, Society, Pharmaceutical industry, Nursing

BROOMFIELD, CO, June 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their Nociscan cost-effectiveness abstract was presented at the International Society for the Advancement of Spine Surgery on Saturday, June 3, 2023.  The cost-effectiveness study comparing Nociscan to provocative discography was performed at the Center for Disruptive Musculoskeletal Innovations (CDMI) through a National Science Foundation (NSF) grant sponsored by Aclarion.  The abstract highlights that Nociscan statistically dominates provocative discography (PD) because PD is both more costly and less effective.

Key Points: 
  • The International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting was held June 1-3, 2023.
  • ISASS Policy Statement on Lumbar Spinal Fusion Surgery acknowledges MR Spectroscopy as an effective alternative to provocative discography.
  • The abstract highlights that Nociscan statistically dominates provocative discography (PD) because PD is both more costly and less effective.
  • “We are pleased with the cost-effectiveness abstract results,” said Ryan Bond, Chief Strategy Officer at Aclarion.

SmithGroup Selects Roxanne Malek as New Managing Partner

Retrieved on: 
Wednesday, June 7, 2023
Science, DNA, K.L.E Society's KLE College of Engineering and Technology, Society, PE, LEED AP, University of California, Berkeley, University, Education, Stanford University, LEED, SmithGroup, Contra Costa Community College District, University of California, San Francisco, California State University, Chico, AP, Partner (business rank), Contra Costa, Higher education, DBIA, American City Business Journals, NCARB, Society for College and University Planning, American Institute of Architects, UC, UC Davis Health Stadium, Risk, Engineering, Growth, Woman, House of Medici, American Institute, AIA, Sykes, Management, Industrial design

Roxanne Malek , AIA, LEED AP BD+C, DBIA has been named as a Managing Partner, joining Russ Sykes , PE, LEED AP and Troy Thompson , AIA, LEED AP to form the three-person team leading the firm.

Key Points: 
  • Roxanne Malek , AIA, LEED AP BD+C, DBIA has been named as a Managing Partner, joining Russ Sykes , PE, LEED AP and Troy Thompson , AIA, LEED AP to form the three-person team leading the firm.
  • Malek succeeds Mike Medici, AIA, NCARB who has served as a Managing Partner with Sykes and Thompson since 2015.
  • Medici, a 42-year veteran of SmithGroup, will support a number of initiatives for the firm through November.
  • Malek has been with SmithGroup for over 25 years, first joining the Science and Technology studio in its San Francisco office.

Revealing How Blood Triggers Brain Disease

Retrieved on: 
Thursday, June 8, 2023
Neuron, Senior, Mendiola Street, Stroke, DSM-IV codes, University of California, San Francisco, Deficit spending, Prognosis, Brain, Research, Multiple sclerosis, Inflammation, Cell, Doctor of Philosophy, Dementia, Biomarker, Blood, Protein, Oxidative stress, Quantitative Biosciences Institute, Gladstone Institutes, Patient, UCSF, Fibrin, Myenteric plexus, Traumatic brain injury, SAN, Immune system, Nature Immunology, Mouse, Microglia, Disability studies, Neurology, Disease, Vaccine, Medical imaging, Alzheimer's disease, MD, Katerina Akassoglou, William Ewart Gladstone

SAN FRANCISCO, June 8, 2023 /PRNewswire/ -- In patients with neurological diseases like Alzheimer's disease and multiple sclerosis, immune cells in the brain known as microglia that normally fulfill beneficial functions become harmful to neurons, leading to cognitive dysfunction and motor impairment. These harmful immune cells may also contribute to age-related cognitive decline in people without dementia.

Key Points: 
  • The scientists discovered that a blood protein called fibrin—which normally aids blood clotting—is responsible for turning on the detrimental genes in microglia, both in Alzheimer's disease and multiple sclerosis.
  • Individuals with neurological diseases like Alzheimer's disease and multiple sclerosis have abnormalities within the vast network of blood vessels in their brain, which allow blood proteins to seep into brain areas responsible for cognitive and motor functions.
  • "These exciting findings change the way we think about blood proteins, from secondary bystanders to primary drivers of harm in the brain," says Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease.
  • "The mechanisms identified in this study could be at work in a range of neurological conditions involving blood leaks in the brain, including neurodegenerative disorders, autoimmune diseases, stroke, and traumatic brain injury.

Artificial Intelligence System Predicts Consequences of Gene Modifications

Retrieved on: 
Wednesday, May 31, 2023
San Francisco, Tissue, Heart, Learning, CRISPR, Broad Institute, Pediatrics, ChatGPT, University of California, San Francisco, Cardiovascular disease, B cell, Research, MIT, Cell, Doctor of Philosophy, Harvard University, Facial muscles, Lung, Protein, UC, MD, Patient, Machine learning, SAN, Map, Kidney, Biology, Artificial intelligence, TEAD4, Cardiomyopathy, AI, Rare, Gladstone Institutes, Gene, Disease, Broad, Genome, Dana–Farber Cancer Institute, Medical imaging, Pharmaceutical industry, Management, Vaccine, Medical device, OpenAI, Andropolia theodori

SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- Researchers at Gladstone Institutes, the Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute have turned to artificial intelligence (AI) to help them understand how large networks of interconnected human genes control the function of cells, and how disruptions in those networks cause disease.

Key Points: 
  • Theodoris and her team used Geneformer to shed light on how heart cells go awry in heart disease.
  • "This approach will greatly advance our ability to design network-correcting therapies in diseases where progress has been obstructed by limited data."
  • Some of those genes, in turn, impact other genes—or loop back and put the brakes on the first gene.
  • However, other potentially important genes identified by Geneformer had not been previously associated with heart disease, such as the gene TEAD4.

Emtrain Announces Collaboration with Workplace Equity Pioneer Joan C. Williams and the Center for WorkLife Law to Launch Series of Online Lessons to Help Eliminate Bias

Retrieved on: 
Wednesday, May 31, 2023
Tug of war, Analytics, Partnership, University, Center for WorkLife Law, Great Resignation, Science and technology in Asia, Mother, Workplace, Woman, University of California, San Francisco, Research, Organization, SAN, Bias, D, Nursing

SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- Emtrain, an eLearning and analytics technology company that develops and measures respect and inclusion in the workplace, today announced a collaboration with Distinguished Professor of Law Joan Williams and the Center for WorkLife Law at the University of California-San Francisco, a pioneer in workplace equity. Launching today are a series of online lessons to help organizations eliminate workplace bias. The microlessons and downloadable toolkits, are based on Joan Williams' Bias Interrupters, which have been proven to drive change in the workplace. 

Key Points: 
  • Launching today are a series of online lessons to help organizations eliminate workplace bias.
  • The microlessons and downloadable toolkits, are based on Joan Williams' Bias Interrupters, which have been proven to drive change in the workplace.
  • "It's an honor and privilege to collaborate with Joan Williams and her team at WorkLife Law.
  • To learn more about Bias Interrupters microlessons and Emtrain's broader suite of eLearning and Analytics, visit our website or contact [email protected] .

Center for Caregiver Advancement Receives $10 Million Grant to Provide Free Training for Caregivers in San Bernardino County

Retrieved on: 
Thursday, May 18, 2023
San Francisco, Workforce, Learning, Pollution, State, IHSS, Partnership, Prevalence, Alzheimer's disease, California Labor and Workforce Development Agency, Disease, Disability, Public, Curriculum, Policy, Abdul Latif Jameel Poverty Action Lab, RCT, University of California, San Francisco, Dignity, CCA, Research, MIT, Respect, Climate change, UC, Access, Growth, Labour, Caregiver, Massachusetts Institute of Technology, Residential care, Nursing

SAN BERNARDINO, Calif., May 18, 2023 /PRNewswire/ -- The Center for Caregiver Advancement (CCA) has been awarded a $10 million grant from the California Workforce Development Board (CWDB) and the Labor and Workforce Development Agency to bring its caregiver training programs to In-Home Supportive Services (IHSS) providers in San Bernardino County. The grant is part of CWDB's HRTP Resilient Workforce Fund.

Key Points: 
  • It will help us provide essential training and resources to caregivers in San Bernardino County, improving both quality of care for consumers and developing specialized skills for workers.
  • Access to CCA's specialized training programs is critical to support older adults and people with disabilities in San Bernardino County.
  • CCA has offered the Alzheimer's care training in Alameda County since 2020, and has started offering it in Los Angeles County this spring.
  • Over 70% of San Bernardino County census tracts have high levels of pollution and are considered disadvantaged areas, according to the CalEnviroScreen index.

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

Retrieved on: 
Wednesday, May 17, 2023
Other Health, Research, Professional Services, Pharmaceutical, Consumer, Clinical Trials, Science, Women, Biotechnology, Finance, Other Science, Health, Epilepsy, San Francisco, University, Therapy, Johns Hopkins Hospital, Internal medicine, Berkeley, BioMarin Pharmaceutical, University of California, San Francisco, Gene editing, Genomics, Dartmouth College, Medication, Patient, Engineering, Marinus, Rare, Medivation, Protagonist, Pharmaceutical industry

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.
  • “Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus.
  • She has significant experience designing and leading rare disease programs from discovery to global regulatory approvals and commercialization.
  • “Marinus has emerged as a leader in the development of innovative treatment options for patients with genetic epilepsies and seizure disorders.

Deepcell Launches AI-Powered Single Cell Analysis Platform to Accelerate Cell Biology Discovery and Catalyze Field of Morpholomics

Retrieved on: 
Wednesday, May 17, 2023
Software, Research, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Artificial Intelligence, Science, Biotechnology, Stem Cells, Health, San Francisco, Cell biology, University, Translational Genomics Research Institute, Microsite, Stanford University, University of California, San Francisco, Microscopy, Cancer, Intelligence, Multimedia, Axon, Cell, Doctor of Philosophy, Stanford University School of Medicine, Thought, MD, Patient, Pathology, Machine learning, Flow cytometry, Developmental biology, Biology, Knowledge, AI, Phenotype, Erasmus MC, Medical device, Microscope, Management, Medical imaging, Reinsurance

Deepcell , a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of the REM-I Platform , a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite.

Key Points: 
  • Deepcell , a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of the REM-I Platform , a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite.
  • By bringing together single cell imaging, sorting, and high-dimensional analysis, the REM-I Platform will catalyze new methods of discovery in a wide range of fields including cancer biology, developmental biology, stem cell biology, gene therapy and functional screening, among others.
  • Despite recent advancements in microscopy and flow cytometry, existing tools for cellular quantification and characterization have left the field of cell biology hypothesis bounded and reliant on human interpretation, until now.
  • In addition to these presentations, the company will also reveal the REM-I instrument and demonstrate its capabilities at the conference.

Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy™ for Cancer

Retrieved on: 
Wednesday, May 17, 2023
Lux Capital, San Francisco, Spark Therapeutics, Beverly Davidson, University, Therapy, University of California, San Francisco, Sutro Biopharma, Cancer, Eric Schmidt, Toxicity, MBA, Civilization, Immunotherapy, Doctor of Philosophy, AAV, Washington University in St. Louis, Founders Fund, Brain, UCSF, Salk Institute for Biological Studies, Engineering, Coronavirus Scientific Advisory Board, Immune system, Annual general meeting, Initial public offering, Neoplasm, Cytokine, Universal, Universal design, Medical imaging, Vaccine, Pharmaceutical industry, Siren

The company’s name was inspired by the powerful signal Universal AAV Immuno-Gene Therapy sends to the immune system, stimulating an immediate and comprehensive anti-tumor response.

Key Points: 
  • The company’s name was inspired by the powerful signal Universal AAV Immuno-Gene Therapy sends to the immune system, stimulating an immediate and comprehensive anti-tumor response.
  • “The world needs big, bold, new ideas to fight cancer, and Universal AAV Immuno-Gene Therapy is exactly that.
  • Our design and engineering of this modality redefines both AAV gene therapy and cytokine immunotherapy, and in doing so, changes the game for cancer treatment,” said Nicole Paulk, PhD, Founder and Chief Executive Officer of Siren.
  • “This is the first AAV gene therapy for cancer and the first AAV gene therapy that is universal, meaning we can make it once and use it for numerous indications.

Spectral Medical Announces First Quarter Results and Provides Corporate Update

Retrieved on: 
Friday, May 12, 2023
University, SAPS, Observational study, Marketing, Baxter, University of California, San Francisco, Clinical trial, Research, Septic shock, Sepsis, Hemoperfusion, ISAC, ESS, Patient, UCSF, PMX, Management, TSX, Mortality, ICU, EDEN, FDA, Pharmaceutical industry, Nursing, Fine chemical, Cryptocurrency

TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update.
  • Importantly, Tigris mortality data continues to exceed our expectations and has been consistent with our recent announcement of the EUPHAS-2 study results .
  • Transition activities are progressing well, with full change from the incumbent CRO expected by the end of the second quarter.
  • The Company concluded the first quarter of 2023 with cash of $4,886,000 compared to $8,414,000 of cash on hand as of December 31, 2022.